CN112587637B

CN112587637B - Multi-effect probiotic preparation with immunity enhancing function and application thereof

Info

Publication number: CN112587637B
Application number: CN202011595609.XA
Authority: CN
Inventors: 刘成; 彭浩
Original assignee: Beijing Yikangbeier Biotechnology Co ltd
Current assignee: Beijing Yikangbeier Biotechnology Co ltd
Priority date: 2020-12-29
Filing date: 2020-12-29
Publication date: 2022-03-15
Anticipated expiration: 2040-12-29
Also published as: CN112587637A

Abstract

The invention provides a multi-effect probiotic preparation with an immune enhancing function and application thereof. The multi-effect probiotic preparation comprises: medicinal plant extracts and probiotics; the medicinal plant extract comprises the following components in parts by weight: 10-20 parts of turmeric extract, 10-15 parts of artichoke extract, 5-10 parts of dendrobium officinale extract and 5-10 parts of astragalus extract; the probiotic comprises the following components: bulgaria lactobacillus, animal bifidobacteria, Swiss lactobacillus, rhamnose lactobacillus, paracasei lactobacillus, cheese lactobacillus and Roy's lactobacillus. The multi-effect probiotic preparation provided by the invention can effectively improve the colonization resistance of probiotics, regulate the micro-ecological environment of intestinal tracts, enhance the immunity of organisms, and has the effects of reducing digestive system diseases such as gastrointestinal tracts and the like, resisting dermatitis, resisting tumors, reducing blood fat and reducing cholesterol.

Description

Multi-effect probiotic preparation with immunity enhancing function and application thereof

Technical Field

The invention belongs to the technical field of microbial medicines, and particularly relates to a multi-effect probiotic preparation with an immune enhancing function and application thereof.

Background

Human and bacteria are symbiont, and the intestinal flora is various bacteria in the intestinal tract, and the number of the bacteria is 10 trillion, which is about 10 times of that of human somatic cells. These intestinal bacteria are mainly divided into three main groups: beneficial bacteria, harmful bacteria and neutral bacteria. Beneficial bacteria, also called probiotics, mainly comprise various bifidobacteria, lactobacilli and the like, can synthesize various vitamins and amino acids necessary for the growth and development of human bodies, participate in the metabolism of saccharides and proteins, and simultaneously promote the absorption of mineral elements such as iron, magnesium, zinc and the like. If the quantity of the harmful bacteria is out of control and the bacteria multiply in large quantities, various diseases can be caused. Neutrophiles have a dual role, e.g. E.coli, enterococci, etc. are normally beneficial to health, and may cause problems once proliferation is out of control, or transfer from the gut to other parts of the body.

Researches show that the balance state of the intestinal flora is closely related to digestive system diseases, endocrine system diseases, mental system diseases, autoimmune diseases and infectious diseases. Therefore, in recent years, with the development of society, people have conducted intensive research on probiotics and gradually understand their probiotic properties.

A plurality of probiotic products are available on the market and are widely applied to food, nutrition and health care, animal breeding and other aspects. However, researches show that different probiotics have different probiotic functions and different action mechanisms for enhancing the body immune function. The change of the mixture ratio combination of different probiotics can play a role in improving the colonization resistance of the probiotics, adjusting the intestinal micro-ecological environment and regulating the immunity of organisms at the same time or play a role in a certain aspect. Therefore, how to reasonably match various beneficial bacteria and promote the release of active bacteria in the human body is the key point for fully playing the roles of different beneficial bacteria in the human body. In addition, the related medicinal substances can supplement beneficial bacteria, and can regulate and promote functions of human body.

Disclosure of Invention

In view of the above, the present invention aims to provide a pleiotropic probiotic preparation with immune function enhancing function and application thereof. The multi-effect probiotic preparation can effectively improve the colonization resistance of probiotics, regulate the micro-ecological environment of intestinal tracts, enhance the immunity of organisms, and has the effects of reducing digestive system diseases such as gastrointestinal tracts and the like, resisting dermatitis, resisting tumors, reducing blood fat and reducing cholesterol.

In order to achieve the purpose, the invention adopts the following technical scheme:

in a first aspect, the present invention provides a pleiotropic probiotic formulation having an enhanced immune function, comprising: medicinal plant extracts and probiotics;

the medicinal plant extract comprises the following components in parts by weight: 10-20 parts of turmeric extract, 10-15 parts of artichoke extract, 5-10 parts of dendrobium officinale extract and 5-10 parts of astragalus extract;

the probiotic comprises the following components in parts by weight: the effective viable count is 1-2 multiplied by 10¹⁰10-20 parts of cfu/g Bulgaria lactobacillus agent and 1-2 multiplied by 10 effective viable count¹⁰20-30 parts of cfu/g animal bifidobacterium bifidum agent with the effective viable count of 1-2 multiplied by 10¹⁰20-30 parts of cfu/g lactobacillus helveticus agent, and the effective viable count of the lactobacillus helveticus agent is 1-2 multiplied by 10¹⁰20-30 parts of cfu/g lactobacillus rhamnosus agent, and the effective viable count is 1-2 multiplied by 10¹⁰20-30 parts of cfu/g lactobacillus paracasei agent with effective viable count of 1-2 multiplied by 10¹⁰10-20 parts of cfu/g lactobacillus casei and 1-2 multiplied by 10 effective viable count¹⁰10-20 parts of cfu/g lactobacillus reuteri.

The invention reasonably matches the medicinal plant extract and the probiotics in a specific proportion, thereby obtaining the probiotic preparation with multiple efficacies, and the preparation can effectively improve the colonization resistance of the probiotics, regulate the micro-ecological environment of intestinal tracts, enhance the immunity of organisms, and has the effects of reducing digestive system diseases such as gastrointestinal tracts and the like, resisting dermatitis, resisting tumors, reducing blood fat, reducing cholesterol and the like.

In the invention, the weight part of the turmeric extract is 10-20 parts; for example, it may be 10 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 18 parts, 20 parts, or the like.

The weight part of the artichoke extract is 10-15 parts; for example, it may be 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, or the like.

The weight part of the dendrobium officinale extract is 5-10 parts; for example, it may be 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, or the like.

The astragalus extract is 5-10 parts by weight; for example, it may be 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, or the like.

The weight part of the Bulgaria lactobacillus is 10-20 parts; for example, it may be 10 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 18 parts, 20 parts, or the like.

The part by weight of the animal bifidobacteria agent is 20-30 parts; for example, it may be 20 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, or the like.

The weight part of the Swiss lactobacillus is 20-30 parts; for example, it may be 20 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, or the like.

The weight part of the rhamnose lactobacillus agent is 20-30 parts; for example, it may be 20 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, or the like.

The weight part of the lactobacillus paracasei is 20-30 parts; for example, it may be 20 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, or the like.

The cheese lactobacillus agent is 10-20 parts by weight; for example, it may be 10 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 18 parts, 20 parts, or the like.

The weight part of the lactobacillus reuteri is 10-20 parts; for example, it may be 10 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 18 parts, 20 parts, or the like.

In one embodiment of the invention, the multi-effect probiotic formulation further comprises a probiotic protectant.

In one embodiment of the invention, the probiotic protecting agent comprises the following components in parts by weight:

50-100 parts of glucan, 30-50 parts of sodium glutamate, 30-50 parts of calcium carbonate, 50-100 parts of casein and 200-300 parts of skimmed milk powder.

Wherein, the weight portion of the glucan can be 50 parts, 55 parts, 60 parts, 65 parts, 70 parts, 75 parts, 80 parts, 85 parts, 90 parts, 95 parts or 100 parts and the like;

the weight parts of the sodium glutamate can be 30 parts, 32 parts, 35 parts, 38 parts, 40 parts, 42 parts, 45 parts, 48 parts or 50 parts and the like;

the calcium carbonate can be 30 parts, 32 parts, 35 parts, 38 parts, 40 parts, 42 parts, 45 parts, 48 parts or 50 parts by weight;

the casein can be 50 parts, 55 parts, 60 parts, 65 parts, 70 parts, 75 parts, 80 parts, 85 parts, 90 parts, 95 parts or 100 parts by weight;

the weight portion of the skimmed milk powder can be 200 parts, 210 parts, 220 parts, 230 parts, 240 parts, 250 parts, 260 parts, 270 parts, 280 parts, 290 parts or 300 parts, etc.

It should be noted that the meaning of the dosage unit "parts" of each component in the medicinal plant extract, the probiotic agent and the probiotic protective agent in the invention is completely the same, i.e. the weight parts of the components are the weight parts of the components in the multi-effect probiotic preparation.

In one embodiment of the invention, the medicinal plant extract and the probiotic are embedded in the probiotic protectant.

In one embodiment of the invention, the multi-effect probiotic preparation is in the form of powder.

In one embodiment of the invention, the particle size of the multi-effect probiotic preparation is 200-400 μm.

In a second aspect, the present invention provides the use of a pleiotropic probiotic formulation according to the first aspect in the manufacture of an anti-dermatitis medicament.

In a third aspect, the present invention provides a use of the pleiotropic probiotic formulation of the first aspect in the preparation of an anti-tumor medicament.

In a fourth aspect, the invention provides a use of the pleiotropic probiotic preparation of the first aspect in preparing a medicament for reducing blood fat and cholesterol.

In a fifth aspect, the present invention provides the use of a pleiotropic probiotic formulation according to the first aspect in the manufacture of a medicament for modulating the gastrointestinal flora.

Compared with the prior art, the invention has the following beneficial effects:

1. according to the invention, the medicinal plant extract and the probiotics are reasonably matched in a specific proportion, so that the obtained multi-effect probiotic preparation can effectively regulate the flora balance of the gastrointestinal tract, promote the colonization growth of the probiotics in the gastrointestinal tract, promote the discharge of vivotoxin and reduce the occurrence of digestive system diseases such as the gastrointestinal tract and the like.

2. According to the invention, the medicinal plant extract and the probiotics are reasonably matched at a specific ratio, so that the obtained multi-effect probiotic preparation can effectively enhance the immunity of a human body, reduce the allergic dermatitis reaction of the human body and has a certain anti-tumor effect.

3. The multi-effect probiotic bacteria also have the effects of reducing blood lipid and cholesterol, and has the effects of keeping body shape, prolonging life, caring skin, and resisting aging.

Drawings

FIG. 1 is a graph of the weight-time curve of mice in an experiment on the effect of multi-effect probiotic powder on the weight of the mice according to an embodiment of the invention.

FIG. 2 is a bar graph of the adipose tissue weight of mice at week 6 in an experiment of the effect of multi-effect probiotic powder on the body weight of the mice according to an embodiment of the present invention.

Detailed Description

The technical scheme of the invention is further explained by the specific implementation mode in combination with the attached drawings. It should be understood by those skilled in the art that the specific embodiments are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.

The raw materials adopted in the embodiment of the invention are as follows:

turmeric extract: shanxi Yongyuan Biotechnology Co., Ltd., product No. YYS-086.

Artichoke extract: shanxi Yongyuan Biotechnology Ltd, product number YYS-005.

The dendrobium officinale extract: semazerumon Biotechnology Ltd.

Astragalus extract: shanxi Yongyuan Biotechnology Ltd, product No. YYS-015.

Lactobacillus bulgaricus powder: effective viable count of 2X 10¹⁰cfu/g

Bifidobacterium animalis powder: effective viable count of 1X 10¹⁰cfu/g

Lactobacillus helveticus powder: effective viable count of 1X 10¹⁰cfu/g

Lactobacillus rhamnosus powder: effective viable count of 2X 10¹⁰cfu/g

Lactobacillus paracasei powder: effective viable count of 1X 10¹⁰cfu/g

Lactobacillus casei powder: effective viable count of 1X 10¹⁰cfu/g

Lactobacillus reuteri powder: effective viable count of 2X 10¹⁰cfu/g

Example 1

The embodiment provides a multi-effect probiotic powder, which comprises the following components in parts by weight:

medicinal plant extract powder, probiotic powder and probiotic protectant;

wherein the medicinal plant extract powder comprises Curcuma rhizome extract 10 parts, globe artichoke extract 10 parts, herba Dendrobii extract 5 parts and radix astragali extract 5 parts;

the probiotic powder contains 10 parts of lactobacillus bulgaricus powder, 20 parts of animal bifidobacterium powder, 20 parts of lactobacillus helveticus powder, 20 parts of lactobacillus rhamnosus powder, 20 parts of lactobacillus paracasei powder, 10 parts of lactobacillus casei powder and 10 parts of lactobacillus reuteri powder;

the probiotic protective agent contains 50 parts of glucan, 30 parts of sodium glutamate, 30 parts of calcium carbonate, 50 parts of casein and 200 parts of skimmed milk powder.

In this embodiment, the preparation method of the multi-effect probiotic powder comprises the following steps:

mixing the above medicinal plant extract powder and probiotic powder in a mixing granulator; dissolving 50 parts of glucan, 30 parts of sodium glutamate, 30 parts of calcium carbonate, 50 parts of casein and 200 parts of skimmed milk powder in 300mL of 0.9% sodium chloride solution, uniformly stirring, adding into a mixing granulator, mixing with probiotic powder and medicinal plant extract powder, preparing into multi-effect probiotic wet granules, and freeze-drying to prepare multi-effect probiotic dry powder of 200-400 mu m.

The content of the probiotics is detected according to the method of GB 4789.35. The content of each active bacterium in the multi-effect probiotic powder prepared in example 1 was determined to be 9X 10⁸cfu/g or more.

Example 2

medicinal plant extract powder, probiotic powder and probiotic protectant;

wherein the medicinal plant extract powder comprises Curcuma rhizome extract 15 parts, globe artichoke extract 12 parts, herba Dendrobii extract 8 parts and radix astragali extract 8 parts;

the probiotic powder contains 15 parts of lactobacillus bulgaricus powder, 25 parts of bifidobacterium animalis powder, 25 parts of lactobacillus helveticus powder, 25 parts of lactobacillus rhamnosus powder, 25 parts of lactobacillus paracasei powder, 15 parts of lactobacillus casei powder and 15 parts of lactobacillus reuteri powder;

the probiotic protective agent contains 80 parts of glucan, 40 parts of sodium glutamate, 40 parts of calcium carbonate, 80 parts of casein and 250 parts of skimmed milk powder.

mixing the above medicinal plant extract powder and probiotic powder in a mixing granulator; dissolving 80 parts of glucan, 40 parts of sodium glutamate, 40 parts of calcium carbonate, 80 parts of casein and 250 parts of skimmed milk powder in 300mL of 0.9% sodium chloride solution, uniformly stirring, adding into a mixing granulator, mixing with probiotic powder and medicinal plant extract powder, preparing into multi-effect probiotic wet granules, and freeze-drying to prepare the multi-effect probiotic dry powder with the particle size of 200-400 microns.

The content of the probiotics is detected according to the method of GB 4789.35. The content of each active bacterium in the multi-effect probiotic powder prepared in example 1 was determined to be 1.6 × 10⁹cfu/g or more.

Example 3

medicinal plant extract powder, probiotic powder and probiotic protectant;

wherein the medicinal plant extract powder comprises Curcuma rhizome extract 20 parts, globe artichoke extract 15 parts, herba Dendrobii extract 10 parts and radix astragali extract 10 parts;

the probiotic powder contains 20 parts of lactobacillus bulgaricus powder, 30 parts of animal bifidobacterium powder, 30 parts of lactobacillus helveticus powder, 30 parts of lactobacillus rhamnosus powder, 30 parts of lactobacillus paracasei powder, 20 parts of lactobacillus casei powder and 20 parts of lactobacillus reuteri powder;

the probiotic protective agent contains 100 parts of glucan, 50 parts of sodium glutamate, 50 parts of calcium carbonate, 100 parts of casein and 300 parts of skimmed milk powder.

mixing the above medicinal plant extract powder and probiotic powder in a mixing granulator; dissolving 100 parts of glucan, 50 parts of sodium glutamate, 50 parts of calcium carbonate, 100 parts of casein and 300 parts of skimmed milk powder in 500mL of 0.9% sodium chloride solution, uniformly stirring, adding into a mixing granulator, mixing with probiotic powder and medicinal plant extract powder, preparing into multi-effect probiotic wet granules, and freeze-drying to prepare the multi-effect probiotic dry powder with the particle size of 200-400 microns.

The content of the probiotics is detected according to the method of GB 4789.35. The content of each active bacterium in the multi-effect probiotic powder prepared in example 1 was determined to be 1.8 × 10⁹cfu/g or more.

Testing the efficacy of the multi-effect probiotic powder:

effect of one or more probiotic powder on gastrointestinal flora of mice

1. Experimental Material

Balb/c mice, SPF grade, female, 12, conventional feed, purchased from Beijing Wittingle laboratory animal technologies, Inc.; 3 kinds of multi-effect probiotic powder provided in examples 1 to 3; the fecal genome DNA extraction kit is purchased from Beijing Tiangen Biochemical technology Co.

2. Experimental methods

2.1 animal grouping and handling

The 12 Balb/c mice were equally divided into A, B, C groups of 3 groups, group A2 were fed with the pleiotropic probiotic powder provided in example 1, and 2 were used as controls; group B2 was fed with the multi-effect probiotic powder provided in example 2, 2 as controls; group C2 was fed with the pleiotropic probiotic powder provided in example 3, 2 only as controls. The experimental group mice were fed with the multi-effect probiotic powder by gavage for 2 weeks, then fed on a normal diet (conventional feed plus distilled water) for 8 days, and the feces of each group of mice were collected every week and stored in a refrigerator at-80 ℃. The grouping and treatment of mice are shown in table 1 below:

table 1 mouse grouping and treatment

2.2 second Generation sequencing and analysis

Feces of each group of mice were collected separately, feces DNA was extracted according to the kit procedures, and 16SrRNA PCR amplification was performed based on the 16SrRNA V3-V4 variable region universal primers (338 forward 5'-ACTCCTACGGGAGGCAGCAG-3'; 806 reverse 5 '-GGACTACHVGGGTWTCTAAT-3'). And recovering PCR products after PCR amplification to construct a library, and performing on-machine sequencing by using HiSeq. Defining a 16SrRNA sequence with similarity higher than 97% as an operation classification unit (OTU), wherein the number of OTUs in a sample is an observed species abundance index, and the species abundance of a reaction sample is increased; 2 OTUs are completely randomly extracted from one sample data, the probability that the OTUs belong to different species is a Simpson index, and the variety diversity of the sample is reflected. And carrying out OTUS clustering and species classification analysis on the effective data obtained by sequencing.

TABLE 2 Effect of pleiotropic probiotic powder on alpha diversity of bacteria in mouse stool samples

From the data in table 2, it can be seen that the observed specific indexes and simpson indexes of 3 experimental mice fed with the multi-effect probiotic powder are significantly higher than those of the control group, which indicates that the multi-effect probiotic powder provided by the invention can obviously regulate the diversity of intestinal flora.

Second, multiple-effect probiotic powder for inhibiting dermatitis reaction of mice

1. Experimental Material

Balb/c mice, SPF grade, female, 10, purchased from Beijing Wittingle laboratory animal technologies, Inc.; 3 kinds of multi-effect probiotic powder provided in examples 1 to 3; ELISA detection kit for mouse serum IgE, TNF-alpha and MCP-1 expression levels is purchased from Wuhan Xindi Biotech limited.

2. Experimental methods

2.1 animal grouping and handling

10 female Balb/c mice were randomly divided into 5 groups of control group, experimental group 1, experimental group 2, experimental group 3, and experimental group 4, with 2 mice per group. Except for the control group, the abdominal hairs of the other 8 mice were shaved, the area of the mice was about 2.5cm × 2.5cm, and 100 μ L of 1.5% DNCB (acetone: olive oil volume ratio: 4:1) solution was applied to the abdominal shaved part for the first sensitization when the experiment was daily; sensitization again after 2 weeks: 20 mu L of 1% DNCB solution is coated on the same position of the inner side and the outer side of the auricle of the mouse, the stimulation is repeated for 3 times every week for 2 weeks, and the model is built for 30 days, so that the ear part of the mouse with successful sensitization can be seen to have erythema, swelling, exudation and incrustation. From the initial sensitization, mice of

experiment groups

1, 2 and 3 are respectively fed with the multi-effect probiotic powder provided by examples 1, 2 and 3 in a gavage mode according to the dose of 0.3 g/kg.d and are continuously fed for 30 days; the control group mice and the experimental group 4 mice were not fed any pleiotropic probiotic powder.

2.2 mouse ear thickness variation

The thickness of the middle of each mouse ear was measured with a vernier caliper from the day of re-sensitization, 1 time before each subsequent DNCB stimulation (i.e., days 14, 17, 20, 23, 26, 29, 30), and the swelling of the appearance of the mouse ears was recorded, as shown in table 3 below:

TABLE 3 left ear thickness (mm) of each group of mice at different times

As can be seen from the table 3, the ears of the mice in the experimental group 4 which are not fed with the multi-effect probiotic powder have strong inflammatory reaction, and the ears are obviously thickened compared with the control group, while the ears of the mice in the three groups which are fed with the multi-effect probiotic powder are thickened compared with the control group, but the thickening amount is less than that of the experimental group 4, which shows that the multi-effect probiotic powder provided by the invention has the anti-dermatitis effect and can inhibit the skin allergic reaction.

2.3 detection of IgE, TNF-alpha and MCP-1 levels in mouse serum

After the experiment for 30 days, the mice are anesthetized by 5% chloral hydrate and sterilized by 75% alcohol, eyeballs are sampled, serum is separated, and the expression levels of IgE, TNF-alpha and MCP-1 in the serum are measured by an ELISA kit according to the kit specification, and the results are shown in the following table 4:

TABLE 4 serum IgE, TNF-alpha and MCP-1 expression levels (pg/mL) in groups of mice

IgE is an important target of atopic dermatitis reaction, and is used as a main catalyst of mast cells, and can stimulate the mast cells to release biological active substances such as cytokines, chemokines, histamine and the like. TNF-alpha is an important proinflammatory mediator and can induce the production of various cytokines in inflammatory responses of patients with dermatitis. MCP-1 may act through mast cell granules to modulate Th1 type immune responses. Therefore, the expression levels of IgE, TNF-alpha and MCP-1 in serum are detected, and the inflammatory response condition of an individual can be predicted. As can be seen from Table 4, the serum expression levels of IgE, TNF-alpha and MCP-1 in the mice of the three groups fed with the multi-effect probiotic powder are higher than those of the control group, but lower than those of the mice of the 4 groups fed with the multi-effect probiotic powder and having inflammatory reaction. The multiple-effect probiotic powder provided by the invention can enhance the self immune function of an organism and enable the organism to generate an anti-dermatitis effect, thereby reducing the level of a cytokine which indicates an inflammatory reaction.

Third, the inhibiting effect of the multi-effect probiotic powder on the tumor of the mouse

1. Experimental Material

Balb/c mice, SPF grade, female, 8, purchased from Beijing Wittingle laboratory animal technologies, Inc.; the 3 kinds of multi-effect probiotic powder provided by the embodiments 1-3. LLT mouse Lewis lung cancer tumor (solid tumor) cell line primary cells were purchased from NTCC type culture collection. ELISA detection kits for mouse serum TNF-alpha, IL-2 and IL-6 were purchased from Wuhan Xindi Biotech Ltd.

2. Experimental methods

2.1 animal grouping and handling

8 Balb/c mice were randomly divided into a control group, an experimental group 1, an experimental group 2, and an

experimental group

3 and 4 groups, each group consisting of 2 mice. Mice were intraperitoneally inoculated with Lewis tumor cells 10⁶One cell/one. Starting the next day after inoculation, the mice in the control group are fed with conventional feed, the mice in the experiment group 1 are fed with the multi-effect probiotic powder and the conventional feed provided in the example 1, the mice in the experiment group 2 are fed with the multi-effect probiotic powder and the conventional feed provided in the example 2, and the mice in the experiment group 3 are fed with the multi-effect probiotic powder and the conventional feed provided in the example 3, wherein the feeding amount of the multi-effect probiotic powder is 0.3 g/kg.d, and the mice are fed in a gastric perfusion mode.

2.2 sample Collection

Feeding the multi-effect probiotic powder for 10 days, anesthetizing the mice by using 5% chloral hydrate, disinfecting by using 75% alcohol, collecting blood from eyeballs, separating serum, and freezing and storing at-80 ℃ for later use. Mice were sacrificed by dislocation, tumor tissue was isolated, tumor weight was weighed with an electronic balance and recorded, and results were analyzed. Calculating the tumor inhibition rate according to the recorded tumor tissue weight, and calculating according to a formula: tumor inhibition rate is (average tumor weight of control group-average tumor weight of experimental group)/average tumor weight of control group x 100%. The results of the experiment are shown in table 5 below:

TABLE 5 antitumor Effect of the Multi-effect probiotic powder on tumor-bearing mice

As can be seen from Table 5, compared with the control group, the tumor weight of the mice in the 3 experimental groups fed with the multi-effect probiotic powder provided by the invention is obviously reduced, which indicates that the multi-effect probiotic powder provided by the invention has a certain tumor inhibition effect.

2.3 detection of expression levels of TNF-alpha, IL-2 and IL-6 in mouse serum

The collected mouse sera were examined by ELISA according to the kit instructions, and the expression levels of TNF-. alpha., IL-2 and IL-6 proteins in each group of mouse sera were calculated based on the measured absorbance, with the results shown in Table 6 below.

TABLE 6 expression levels (pg/mL) of TNF-. alpha.IL-2 and IL-6 in mouse sera

As can be seen from Table 6, compared with the control group, the levels of TNF-alpha, IL-2 and IL-6 in the serum of the mice fed with the multi-effect probiotic powder are all obviously reduced, and the cytokines are cytokines which mediate chronic inflammatory reaction, regulate the immune function of the body and play the role of resisting tumors, and the levels of the cytokines are reduced, so that the influence of the tumors is reduced, which shows that the multi-effect probiotic powder provided by the invention can enhance the immune function of the body, thereby having the function of inhibiting the tumors.

Four, influence of multi-effect probiotic powder on body weight of mice

1. Experimental Material

Balb/c mice, SPF grade, female, 18, high fat diet, conventional diet purchased from Beijing Wintolite laboratory animal technologies, Inc.; the 3 kinds of multi-effect probiotic powder provided by the embodiments 1-3.

2. Experimental methods

2.1 animal grouping and handling

18 Balb/c mice were equally divided into A, B, C total groups of 3: group a 2 mice were used as experimental group 1, and were fed the multi-effect probiotic powder, high-fat diet and distilled water provided in example 1; 2 mice were used as control 1, fed with conventional feed and distilled water; 2 mice served as control 2, fed high fat diet and distilled water; group B2 mice were used as experimental group 2, and were fed the multi-effect probiotic powder, high-fat diet and distilled water provided in example 2; 2 mice served as control 3, fed regular feed and distilled water; 2 mice served as control 4, fed high fat diet and distilled water; group C2 mice were taken as experimental group 3 and fed the multi-effect probiotic powder, high-fat diet and distilled water provided in example 3; 2 mice served as control 5, fed regular feed and distilled water; 2 mice served as control 6, and were fed high fat diet and distilled water. Mice were continuously fed for 6 weeks, and the body weights of the mice were measured at day 0, week 1, week 2, week 3, week 4, week 5 and week 6, respectively, after which the mice were dissected to collect adipose tissues and weighed.

Table 7 mouse grouping and treatment

2.2 mouse body weight and adipose tissue weight changes

From the mouse body weight and the adipose tissue weight, a mouse body weight-time graph (shown in fig. 1) and a mouse adipose tissue weight histogram at week 6 (shown in fig. 2) were plotted.

As can be seen from fig. 1, the body weight of the mice fed with the high-fat diet without the multi-effect probiotic powder (

controls

2, 4, 6) was significantly increased compared to the mice fed with the conventional diet (

controls

1, 3, 5), whereas the body weight of the mice fed with the high-fat diet and the multi-effect probiotic powder (

experimental groups

1, 2, 3) was hardly increased within 6 weeks, and the difference from the body weight of the mice fed with the conventional diet was insignificant.

As can be seen from fig. 2, the mice fed the multi-effect probiotic powder (

experimental groups

1, 2, 3) had significantly less weight of mesenteric, perihepatic and perirenal fat than the mice fed the high fat diet without the multi-effect probiotic powder (

controls

2, 4, 6). The multi-effect probiotic powder provided by the invention can effectively reduce blood fat and cholesterol, reduce fat accumulation and help to maintain body type.

Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims

1. A pleiotropic probiotic formulation with immune-enhancing, anti-dermatitis and anti-tumor effects, comprising: medicinal plant extracts and probiotics;

the probiotic preparation comprises the following components in parts by weight: the effective viable count is 1-2 multiplied by 10¹⁰10-20 parts of cfu/g Bulgaria lactobacillus agent and 1-2 multiplied by 10 effective viable count¹⁰20-30 parts of cfu/g animal bifidobacterium bifidum agent with the effective viable count of 1-2 multiplied by 10¹⁰20-30 parts of cfu/g lactobacillus helveticus agent, and the effective viable count of the lactobacillus helveticus agent is 1-2 multiplied by 10¹⁰20-30 parts of cfu/g lactobacillus rhamnosus agent, 1-2 effective viable count and high yield10¹⁰20-30 parts of cfu/g lactobacillus paracasei agent with effective viable count of 1-2 multiplied by 10¹⁰10-20 parts of cfu/g lactobacillus casei and 1-2 multiplied by 10 effective viable count¹⁰10-20 parts of cfu/g lactobacillus reuteri;

the multi-effect probiotic preparation also comprises a probiotic protective agent, wherein the probiotic protective agent comprises the following components in parts by weight:

2. The multi-effect probiotic formulation according to claim 1, characterized in that said medicinal plant extract and probiotics are embedded in said probiotic protectant.

3. The multi-effect probiotic formulation according to claim 1, characterized in that it is in the form of a powder.

4. The multi-effect probiotic formulation according to claim 3, characterized in that it has a particle size of 200-400 μm.

5. Use of a pleiotropic probiotic formulation according to any one of claims 1 to 4 for the preparation of an anti-dermatitis medicament.

6. Use of a pleiotropic probiotic formulation according to any one of claims 1 to 4 for the preparation of an antitumoral medicament.

7. Use of a pleiotropic probiotic formulation according to any one of claims 1 to 4 for the preparation of a medicament for lowering blood lipids and cholesterol.

8. Use of a pleiotropic probiotic formulation according to any one of claims 1 to 4 for the preparation of a medicament for modulating the gastrointestinal flora.